Advance Precision Medicine, Drug Development & Gene Therapy Approaches for More Curative Treatment of Heart Failure & Rare Cardiomyopathies
Welcome to the 2nd HFpEF & HCM Drug Discovery & Development Summit
The Industry's Only Definitive Forum for Cardiovascular Drug Discovery & Development
As BioCardia’s off-the shelf cell therapy for HFpEF enters first-in-human study and AstraZeneca meets its primary endpoint in phase III, bipharma are racing to bring disease-modifying therapies to the world’s biggest killer.
Uniting industry leaders from Pfizer, Eli Lilly, Regeneron, Bayer and more, the 2nd HFpEF & HCM Drug Discovery & Development Summit is dedicated to redefining the new standard of care with precision medicine and regenerative therapies.
Join the exclusive forum dedicated to interrogating the latest progress in precision cardiology, implementing gene therapy, and constructing cost-effective phase II trials with multiple endpoints in interconnected organ systems.
With more speakers, more content on wider cardiomyopathies including amyloidosis, HCM, and Duchenne’s, and a greater focus on networking than ever before, do not miss this opportunity to get market intelligence from the commercially important and growing, cardiovascular R&D field.
World-Class Speaker Faculty Includes:
Vice President - Worldwide Research & Development
Vice President - Global Translational Medicine & Head of Cardiovascular & Metabolism
Director & QSP, Cardiovascular Lead
Bristol Myers Squibb
Check out what some of our speakers have to say:
"I look forward to discussing the historical evolution in thinking about the syndrome of HFpEF and the pitfalls of continuing to think in a traditional paradigm"
Javed Butler, Director of Cardiovascular Medicine, Stony Brook Medicine
"The opportunity to meet and discuss a topic as complex as HFpEF in a dedicated meeting with ample time and with a common goal does not come often and is highly appreciated."
Ola Vedin, Global Medical Director, Heart Failure, Boehringer Ingelheim
"Developing a deeper understanding of mechanisms underlying HFpEF for development of novel therapeutics that may combat this disease."
Rachel Roth Flach, Senior Principle Scientist, Pfizer